摘要
目的探讨MUC1、MUC2在原发性胆囊癌组织中的表达及其在胆囊癌诊断和免疫治疗中的意义。方法采用免疫组化方法检测42例原发性胆囊癌组织和17例正常胆囊组织中MUC1、MUC2的表达。结果MUC1﹑MUC2在胆囊癌组织中的阳性表达率分别为76.19%和47.62%;明显高于正常胆囊组织(29.41%)(P=0.001)和11.76%(P=0.010)。MUC1、MUC2在胆囊癌组织中的阳性表达率与正常胆囊组织之间存在统计学差异(P<0.05)。MUC1、MUC2在胆囊癌组织中阳性表达率与胆囊癌组织病理类型、组织学分化、淋巴结转移及Nevin分期也有相关关系。但与有无合并胆囊结石无相关关系。结论MUC1、MUC2可作为胆囊癌患者预后评价指标,有可能作为肿瘤微转移的诊断及免疫治疗的靶抗原。
Objective To investigate the expression of MUC1 and MUC2 in primary carcinoma of the gall bladder (PCG) and its clinical significance in the diagnosis and immunotherapy of PCG. Methods The expression of MUC1 and MUC2 were examined by immunothistochemical analysis in 42 samples of primary carcinoma of the gall bladder(PCG) and 17 samples of normal gall bladder tissues. Results Immunothistochemical analysis showed that the positive rate of MUC1 and MUC2 in PCG was 76.19% and 47.62%,much higher than that in normal gall bladder tissues(29.41%and ll.76%),The expression levels of MUC1 and MUC2 in PCG was significandy higher than that in normal gall bladder tissues (P〈0.05).expression levels of MUC1 and MUC2 in PCG had statistically correlation with pathological types , differentiation ,lymph node status and Nevin staging. But the expression of MUC1 and MUC2 was not related to the gallstone. Conclusion Over-expression and localization of MUC1 and MUC2 in primary carcinoma of the gall bladder may act as distinguishing diagnostic markers of PCG, and also might be as the target of immunotherapy of PCG.
出处
《海南医学》
CAS
2008年第7期13-14,31,共3页
Hainan Medical Journal